Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5919_Библиотеки_им_академика_М_И_Перельмана.pdf
Drug Delivery to the Musculoskeletal System: Localized Therapies and Repair 369
Fig. 5 (a) Surface modification of SWCNT for bio-applications (from Ref. [14] with permission); (b) small-dotted
circle in the nuclei of live HeLa cells contain FITC-PEG-SWCNTs; (c) FRAP analysis of the intracellular FITCPEG-SWCNTs, Blue: Free FITC bead-loaded; Green: FITC-PEG-SWCNTs bead-loaded; Red: FITC-PEG-SWCNTs
internalized by incubation for 48 h (b and c reprinted with permission from Ref. [
8])
3.4 Small Molecule Delivery System
3.4.1 Intraarticular Delivery System
– In biomedical applications, near-infrared (NIR) light with
wavelengths ranging from 650 to 900 nm is mostly utilized
for deeper light penetration, meaning more than a few
millimeters [
1].
For musculoskeletal tissue repair and regeneration, small therapeutics have emerged as promising drug delivery approaches that can
reduce the drawbacks of growth factors, such as immunogenic
reactions, contamination issues, and protein instability [
7].
Using polyethylene glycol-modified single-walled carbon nanotubes (PEG-SWCNTs) (Fig.
5a), Sacchetti et al. created a novel
intraarticular delivery method that delivered gene inhibitors while
remaining in the joint cavity and penetrating the car tilage matrix to
treat osteoarthritis.
Procedure
(i) PEG-SWCNTs were
loaded
with morpholino antisense oligo-
mers (mASOs) against green fluorescence protein (GFP).
(ii) Small regions
(dotted circle) in the nuclei of live HeLa cells
containing fluorescein isothiocyanate (FITC)-PEG-SWCNTs
internalized after an incubation of 48 h (Fig.
5b).
370 Khumtya Debbarma et al.
(iii) Recovery of fluorescence intensities in the bleached area ana-
lyzed by FRAP (Fluorescence recovery after Photobleaching):
Fig. 5c.
Blue data: Free FITC.
Green data: Bead-loaded FITC-PEG-SWCNTs.
Red data: FITC-PEG-SWCNTs internalized by incubation for
(iv) These loaded particles were then injected intraarticularly into
the knees.
48 h.
3.5 Gene Delivery System
3.5.1 Ex Vivo/Indirect
Gene Transfer [
3.5.2 In Vivo/Direct Gene
Transfer [
13]
25]
Another new approach to treating musculoskeletal disorders is gene
delivery, which allows for the localized, regulated expression of
therapeutic nucleic acids and or proteins.
Vector is a gene therapy primer that allows desired gene
(cDNA) to insert into the host cells in a way that make them easier
to translocate to the nucleus and produce high levels of transgenic
expression.
(i) The desired vector is taken up and transduced into the target
cells.
(ii) They are subsequently selected and amplified.
(iii) After that, the genetically modified cells can be directly trans-
ferred to the location of musculoskeletal injury or they can be
implanted into a scaffold (Fig. 6b).
(i) Direct gene transfer is the process of introducing the gene
transfer vector directly to the site of musculoskeletal injury.
Fig. 6 (a, b) Schematic image showing gene transfer therapy. (Reprinted with permission from Ref. [3])
Drug Delivery to the Musculoskeletal System: Localized Therapies and Repair 371
(ii) This will further allow the cells that come into contact with the
vector to take up the desired/target gene and to express and
secrete the transgenic products locally (Fig. 6a).
3.6 Stem Cell Technology
4 Conclusion
Transformative approaches in clinical musculoskeletal repair and
regeneration involve the use of tissue engineering techniques to
correct disorders, resulting from tumor removal. Cell-based treatments in musculoskeletal drug delivery have been particularly
driven by stem cell engineering, which has the potential to promote
the healing of disorders and injured tissues [
31].
Procedure
(i) Stem cells are progenitor cells derived mostly from bone mar-
row and injected directly into tissues to facilitate tissue repair.
(ii) Bone marrow–derived mesenchymal stem cells possess poten-
tial for chondrogenesis, osteogenesis and radiogenesis.
(iii) These cells support the formation of bone by osteogenesis,
adipose tissue by adipogenesis, cartilage by chondrogenesis,
muscle by myogenesis, and tendon/ligament formation by
tendogenesis/ligamentogenesis after differentiating into mesenchymal progenitor cells (Fig.
7).
Drug delivery has attracted growing interest as an efficacious therapeutic approach for treating a variety of musculoskeletal disorders,
including infection, tumor, cancer, etc. In order to achieve precisely
controlled and on-demand drug delivery for musculoskeletal treatments, many new concepts have been proposed and studied. These
include the development of new drugs (such as genes, small molecule therapeutics, stem cells, etc.), innovative tools (such as 3D
printing, tissue engineering technique, etc.), and novel delivery
strategies (such as multiple delivery, smart stimuli-responsive delivery, etc.), the results usually show improved outcomes in treating
various musculoskeletal disorders.
In conclusion,
new systems incorporating cutting-edge therapeutic methodologies are always emerging, but current musculoskeletal delivery systems are still in their infancy and required
additional in vivo or clinical research. Clinical investigations for
the treatment of common and uncommon musculoskeletal disorders will continue to be motivated by the study of drug delivery due
to the swift advancement of new therapeutic medications and delivery methods, as well as the potential of sophisticated drug delivery
systems as discussed here.
372 Khumtya Debbarma et al.
Fig. 7 Mesenchymal stem cell (MSC) differentiation. (Adapted from Ref. [
References
1. Alvarez-Lorenzo C, Bromberg L, Concheiro A
(2009) Light-sensitive intelligent drug delivery
systems. Photochem Photobiol 85:848–860
2. Banerjee H, Shen S, Ren H (2018) Magnetically actuated minimally invasive microbots for
biomedical applications. Electromagnetic
Actuation and Sensing in Medical Robotics,
pp 11–41
3. Bhat P, Garibyan L (2022) The potential of
CRISPR-guided therapies in the dermatology
clinic. JID Innov 2(4):100103
4. Binder KW, Allen AJ, Yoo JJ, Atala A (2011)
Drop-on-demand inkjet bioprinting: a primer.
Gene Ther Regul 06:33–49
5. Briggs AM, Woolf AD, Dreinho¨fer K,
Homb N, Hoy DG, Kopansky-Giles D,
Akesson K, March L (2018) Reducing the
global burden of musculoskeletal conditions.
Bull W H O 96:366–368
6. Chen H, Zeng X, Tham HP, Phua SZF,
Cheng W, Zeng W, Shi H, Mei L, Zhao Y
(2019) NIR-light-activated combination therapy with a precise ratio of photosensitizer and
prodrug using a host-guest strategy. Angew
Chem 131:7723 –7728
7. Chen Y, Huang J, Tang C, Chen X, Yin Z,
Heng BC, Chen W, Shen W (2017) Small molecule therapeutics for inflammation-associated
chronic musculoskeletal degenerative diseases:
past, present and future. Exp Cell Res 359:1–9
8. Cheng J,
Reversible accumulation of PEGylated singlewalled carbon nanotubes in the mammalian
nucleus. ACS Nano 2(10):2085–2094
20])
Veca LM, Lamond A et al (2008)
Drug Delivery to the Musculoskeletal System: Localized Therapies and Repair 373
9.
Di J, Kim J, Hu Q, Jiang X, Gu Z (2015)
Spatiotemporal drug delivery using lasergenerated-focused ultrasound system. J Control Release 220:592–599
10. Dixon SJ, Chidiac P (2018) Editorial overview:
musculoskeletal: new therapeutic targets and
delivery systems. Curr Opin Pharmacol 40:ix–
xi
11. Estelrich J, Escribano E, Queralt J, Busquets
MA (2015) Iron oxide nanoparticles
magnetically-guided and magneticallyresponsive drug delivery. Int J Mol Sci 16:
8070–8101
12. Evans CH, Huard J (2015) Gene therapy
approaches to regenerating the musculoskeletal
system. Nat Rev Rheumatol 11:234–242
13. Evans CH (2007) Facilitated endogenous
repair: making tissue engineering simple, practical, and economical. Tissue Eng 13:1987–
1993
14. Gao Z, Varela JA, Groc L, Lounis B (2015)
Toward the suppression of cellular toxicity
from single-walled carbon nanotubes. Biomaterials. Science 4(2):230
15. Geiger BC, Grodzinsky AJ, Hammond PT
(2018) Designing drug delivery systems for
articular joints. Chem Eng Prog 114:46–51
16. Gulzar A, Gai S, Yang P, Li C, Ansari MB, Lin J
(2015) Stimuli responsive drug delivery application of polymer and silica in biomedicine. J
Mater Chem B 3:8599–8622
17. Im GI (2018) Application of kartogenin for
musculoskeletal regeneration. J Biomed Mater
Res Part A 106:1141–1148
18. Johnson RW, Sowder ME, Giaccia AJ (2017)
Hypoxia and bone metastatic disease. Curr
Osteoporos Rep 15:231–238
19. Kocak G, Tuncer C, Bu¨tu¨n V (2017)
pH-responsive polymers. Polym Chem 8:144–
176
20. Hankenson KH (2020) 49 Stem cells for musculoskeletal repair. Musculoskeletal Key
21. Kwee BJ, Mooney DJ (2017) Biomaterials for
skeletal muscle tissue engineering. Curr Opin
Biotechnol 47:16–22
22. Loebel C, Burdick JA (2018) Engineering stem
and stromal cell therapies for musculoskeletal
tissue repair. Cell Stem Cell 22:325–339
23. Lu Y, Sun W, Gu Z (2014) Stimuli-responsive
nanomaterials for therapeutic protein delivery.
J Control Release 194:1–19
24. Manzano M, Vallet-Regı´ M (2012) Revisiting
bioceramics: bone regenerative and local drug
delivery systems. Prog Solid State Chem 40:
17–30
for
25. Minas T (2012) A primer in cartilage repair. J
Bone Joint Surg 94:141–146
26. Mirani B, Pagan E, Shojaei S, Dabiri SMH,
Savoji H, Mehrali M, Sam M, Alsaif J, Bhiladvala RB, Dolatshahi-Pirouz A, Radisic M,
Akbari M, Facile. (2020) Method for fabrication of meter-long multifunctional hydrogel
fibers with controllable biophysical and biochemical features. ACS Appl Mater Interfaces
12:9080–9089
27. Mura S, Nicolas J, Couvreur P (2013) Stimuliresponsive nanocarriers for drug delivery. Nat
Mater 12:991–1003
28. Newman MR, Benoit DS (2016) Local and
targeted drug delivery for bone regeneration.
Curr Opin Biotechnol 40:125–132
29. Padilla S, Sanchez M, Orive G, Anitua E
(2017) Human-based biological and biomimetic autologous therapies for musculoskeletal
tissue regeneration. Trends Biotechnol 35:
192–202
30. Peddada KV, Peddada KV, Shukla SK,
Mishra A, Verma V (2015) Role of curcumin
in common musculoskeletal disorders: a review
of current laboratory, translational, and clinical
data. Orthop Surg 7:222–231
31. Pourquie
long road to making muscle in vitro. Curr Top
Dev Biol 129:123–142
32. Rasel SI, Mohona FA, Akter W et al (2022)
Exploration of site-specific drug targeting—a
review on EPR-, stimuli-, chemical-, and
receptor-based approaches as potential drug
targeting methods in cancer treatment. J
Oncol 48:1–26
33. Sahle FF, Gulfam M, Lowe TL (2018) Design
strategies for physical-stimuli-responsive programmable nanotherapeutics. Drug Discov
Today 23:992–1006
34. Santos SS, Gonzaga RV, Silva JV, Savino DF,
Prieto D, Shikay JM, Silva RS, Paulo LHA,
Ferreira EI, Giarolla J (2017) Peptide dendrimers: drug/gene delivery and other
approaches. Can J Chem 95:907–916
35. Sorkio A, Koch L, Koivusalo L, Deiwick A,
Miettinen S, Chichkov B, Skottman H (2018)
Human stem cell based corneal tissue mimicking structures using laser-assisted 3D bioprinting and functional bioinks. Biomaterials 171:
57–71
36. Stringer J, Derby B (2010) Formation and
stability of lines produced by inkjet printing.
Langmuir 26:10365–10372
37. Tagami T, Foltz WD, Ernsting MJ, Lee CM,
Tannock IF, May JP, Li SD (2011) MRI
´
O, Al Tanoury Z, Chal J (2018) The
374 Khumtya Debbarma et al.
monitoring of intratumoral drug delivery and
prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials 32:6570–6578
38. Torchilin VP (2014) Multifunctional,
stimulisensitive nanoparticulate systems for drug
delivery. Nat Rev Drug Discov 13:813–827
39. Tuan RS (2013) Regenerative medicine in
2012: the coming of age of musculoskeletal
tissue engineering. Nat Rev Rheumatol 9:74–
76
40. Vinay R, Kusum DV (2016) Potential of targeted drug delivery system for the treatment of
bone metastasis. Drug Deliv 23:21–29
41. Vulic K, Shoichet MS (2014) Affinity-based
drug delivery systems for tissue repair and
regeneration. Biomacromolecules 15:3867–
3880
42. Wang Z, Abdulla R, Parker B, Samanipour R,
Ghosh S, Kim K (2015) A simple and highresolution stereolithography-based 3D bioprinting system using visible light crosslinkable
bioinks. Biofabrication 7:045009
43. Wang Z, Kumar H, Tian Z, Jin X, Holzman JF,
Menard F, Kim K (2018) Visible light
photoinitiation of cell-adhesive gelatin methacryloyl hydrogels for stereolithography 3D bioprinting. ACS Appl Mater Interfaces 10:
26859–26869
44. Wang Z, Wen F, Lim PN, Zhang Q, Konishi T,
Wang D, Teoh SH, Thian ES (2017) Nanomaterial scaffolds to regenerate musculoskeletal
tissue: signals from within for neovessel formation. Drug Discov Today 22:1385–1391
45. Xia H, Zhao Y, Tong R (2016) Ultrasoundmediated polymeric micelle drug delivery, in:
therapeutic ultrasound, country. Ther
Ultrasound
46. Zardad AZ, Choonara YE, Toit LCD,
Kumar P, Mabrouk M, Kondiah PPD, Pillay V
(2016) A review of thermo-and ultrasoundresponsive polymeric systems for delivery of
chemotherapeutic agents. Polymers 8:359
47. Zhang S, Xing M, Li B (2018) Biomimetic
layer-by-layer self-assembly of nanofilms, nanocoatings, and 3D scaffolds for tissue engineering. Int J Mol Sci 19:1641
48. Ziemba AM, Gilbert RJ (2017) Biomaterials
for local, controlled drug delivery to the
injured spinal cord. Front Phar macol 8:245
Chapter 17
Drug Delivery to the Reproductive System: Innovations
and Therapeutic Advances
Dhaval J. Kamothi , Ayushi Vaidhya, Nabaneeta Smaraki,
and Harsh R. Jogi
Abstract
The reproductive system poses distinct physiological challenges for effective drug delivery, necessitating
innovative strategies to navigate various biological barriers, including the blood-testis barrier, vaginal
mucosa, and cervix. Targeted drug delivery is essential for addressing prevalent conditions that require
therapeutic intervention, such as reproductive cancers, infertility, and sexually transmitted infections.
Recent advancements in drug delivery systems, particularly those utilizing nanotechnology, have demonstrated significant potential in enhancing the therapeutic efficacy of various agents. Platforms like nanoparticles and liposomes facilitate targeted drug delivery, whereas hydrogels and biodegradable polymers
enable localized and controlled release of therapeutics. Innovations in injectable and implantable systems,
such as drug-eluting intrauterine devices and subdermal implants, have further optimized sustained drug
release mechanisms. Additionally, micro- and nano-needles offer minimally invasive methods for direct
administration to reproductive tissues. Route-specific delivery methods, including vaginal, uterine, and
penile applications, have been investigated to improve bioavailability and patient compliance. Moreover,
targeted and precision medicine approaches, encompassing gene therapy and personalized medicine, are
advancing tailored treatment protocols based on individual genetic and molecular profiles. The therapeutic
landscape includes applications in assisted reproductive technologies and the management of reproductive
cancers and infections, highlighting the transformative potential of advanced drug delivery systems to
enhance patient outcomes. Nonetheless, considerations regarding safety and regulatory compliance remain
paramount in the development and application of these innovative therapies, emphasizing the need for
ongoing research in this critical domain of reproductive health.
Key words Targeted drug delivery, Nanoparticles, Hydrogels, Intrauterine devices, Micro-needles,
Gene therapy, Personalized medicine
1 Introduction
Reproductive health is a complex and comprehensive concept that
includes the physical, mental, and social dimensions of well-being
as they relate to the reproductive system and its functions. According to the World Health Organization (WHO), reproductive health
375
376 Dhaval J. Kamothi et al.
refers to a state of complete well-being in these aspects, beyond
merely the absence of disease or dysfunction in relation to the
reproductive system and its processes [
tional Conference on
tified five key components essential for sexual and reproductive
health care: (1) enhancing services related to antenatal, perinatal,
postpartum, and newborn care; (2) providing comprehensive family planning services, including treatments for infertility; (3) reducing the incidence of unsafe abortions; (4) fostering overall sexual
and reproductive health; and (5) addressing v
conditions of the
sexually transmitted diseases (STDs), and gynecological disorders
. Various strategies have been embraced by the scientific com-
[
3]
munity
chapter will examine innovative methods created by researchers
globally to address the physical and medical challenges associated
with sexual and reproductive health.
to sexual and reproductive health is crucial. Individuals of all genders can experience a range of health issues, which can be categorized into four main groups: first, infectious diseases, including
sexually transmitted infections like human immunodeficiency
virus (HIV) [
uterine, and ovarian cancers in women, as well as prostate cancer in
men [5, 6]; third, infertility, which may arise from factors related to
either gender and often necessitates the use of assisted reproductive
technology (ART) for treatment [
such as endometriosis, fibroids, and polycystic ovary syndrome
[8, 9].
1, 2
]. The Cairo Interna-
Population and Development in 2004 iden-
arious pathological
reproductive system, such as cancer, infections,
enhance
to
Understanding the physical and pathological challenges related
sexual and reproductive health services. This
4]; second, various cancers, such as breast, cervical,
7]; and finally, other conditions
2 Importance of Targeted Drug Delivery to the Reproductive System
Targeted drug delivery systems (TDDSs) are designed to deliver
drug precisely to the tumor site, enhancing efficacy and minimizing
side effects. This is particularly important in treating ovarian cancer,
which has a high mortality rate and poor prognosis due to extensive
10].
abdominal metastasis and late diagnosis [
ductive system is prone to various infections, injuries, and physiological changes. Advanced drug delivery platforms can significantly
improve the treatment of these conditions by targeting specific cell
populations or intracellular environments. TDDSs allow for controlled drug release, which is essential for maintaining therapeutic
drug levels over extended periods. This is beneficial in managing
chronic conditions and reducing the frequency of drug administration [
10].
Advanced drug delivery approaches are being developed
for biopharmaceuticals, including vaccines, antibiotics, nucleic
acids, proteins, and peptides. These approaches can enhance the
The human repro-
Advances in Drug Delivery to the Reproductive System 377
delivery and effectiveness of these complex molecules in the reproductive system. In ovarian cancer, chemoresistance is a significant
challenge. TDDSs can help overcome this by ensuring that higher
concentrations of the drug reach the tumor site, thereby improving
the overall treatment outcome.
3 Challenges in Drug Delivery to the Reproductive System
The challenges in drug delivery to the reproductive system are
multifaceted and can significantly impact the effectiveness of treatments for infertility and related conditions. One of the primary
challenges is the anatomical and physiological barriers that drugs
must overcome to reach their target sites within the female reproductive tract (FRT). The unique environment of the FRT, including its mucosal barriers and varying pH levels, can hinder the
absorption and efficacy of therapeutic agents [
traditional drug delivery methods often face limitations such as
short contact time with the mucosa and variability in individual
anatomy, which necessitate the development of innovative delivery
systems [
(UGT) encounters multiple obstacles that can be categorized as
anatomical, physiological, or behavioral. These challenges encompass the local epithelial barrier, the presence of drug transporters
and metabolizing enzymes, the composition of the surrounding
tissue (including immune cells), the influence of microbiota, the
hormonal environment, the adequacy of blood supply and lymphatic drainage, the existence of dynamic fluids with intricate compositions, the necessity for sterility, the risk of non-target drug
exposure, potential side effects, and the overall anatomical accessibility of the region [
infertility treatments. High costs associated with assisted reproductive technologies (ART) and the lack of adequate insurance coverage can lead to delays or discontinuation of therapy, particularly
among low-income populations [
scores the need for health sector authorities to develop costeffective solutions and improve access to ART services, ensuring
that financial constraints do not prevent couples from receiving
necessary treatments [
lenges, including physiological barriers, the need for innovative
delivery systems, and economic constraints. Addressing these issues
through advancements in nanotechnology and policy changes can
enhance the effectiveness of treatments for infertility and improve
overall reproductive health outcomes.
13].
The administration of drugs to the upper gastrointestinal tract
14].
Financial b
Drug
arr
iers also pose significant challenges to accessing
15]. This economic aspect under-
15]
.
delivery to the reproductive system faces several chal-
11, 12]. For instance,
378 Dhaval J. Kamothi et al.
Nanotechnology and other techniques has emerged as a
promising solution to enhance drug delivery in reproductive
health. The use of nanocarriers can improve the bioavailability of
drugs while minimizing side effects, thereby creating more effective
treatment regimens [
release drugs in a controlled manner, targeting specific tissues
within the reproductive system and potentially increasing the therapeutic outcomes for conditions such as endometriosis and uterine
fibroids [
17]. Moreover, advancements in sol-gel formulations have
shown potential for intravaginal drug delivery, offering a versatile
platform for the administration of various therapeutic agents [11].
4 Advances in Drug Delivery Systems
The advanced drug delivery systems include use of delivery systems
such as nanoparticles, liposomes, hydrogels and polymer gels,
micro and nano needles and others (Fig.
12, 16]. These systems can be designed to
1).
4.1 NanotechnologyBased Delivery
Systems
Nanomedicine represents a biotechnological strategy for the delivery of therapeutics, employing nanoparticles (NPs) to facilitate the
diagnosis, prognosis, and treatment of various medical conditions
18]. Due to their nanoscale dimensions, specifically those measur-
[
ing less than 100 nm, NPs exhibit unique properties that allow for
targeted drug delivery and protection of therapeutic agents
19]. The functionalization of NP surfaces improves the selective
[
targeting of particular cells or tissues, while the encapsulation of
therapeutic agents minimizes metabolic degradation and extends
Fig. 1 Representative images of the different advanced drug delivery systems